Trial Profile
A Phase I Trial of ABT-263 (Navitoclax), a Bcl-2 Inhibitor, and Sorafenib (Nexavar) in Patients With Relapsed or Refractory Solid Organ Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 01 Mar 2024
Price :
$35
*
At a glance
- Drugs Navitoclax (Primary) ; Sorafenib (Primary)
- Indications Liver cancer; Solid tumours
- Focus Adverse reactions
- 20 Jan 2024 Results (n=25) assessing safety was determined were presented at the 2024 Gastrointestinal Cancers Symposium.
- 09 May 2023 Planned End Date changed from 30 Nov 2022 to 7 May 2024.
- 26 Jul 2022 Planned End Date changed from 1 Aug 2022 to 30 Nov 2022.